Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MK-3120 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on MK-3120, a putative antibody-drug conjugate (ADC) targeting Nectin-4 (Apr 2025). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MK-3120 | MK3120|MK 3120|SKB 410|SKB-410|SKB 410 | NECTIN4 Antibody 11 | Limited information is currently available on MK-3120, a putative antibody-drug conjugate (ADC) targeting Nectin-4 (Apr 2025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06818643 | Phase I | MK-3120 | A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) | Recruiting | USA | TUR | NLD | ISR | FRA | ESP | 5 |
| NCT07222488 | Phase Ib/II | MK-3120 | A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) | Recruiting | USA | 0 |